Oceanic Breakthroughs: Marine-Derived Innovations in Vaccination, Therapy, and Immune Health

Area of Science:

• Marine biotechnology
• Vaccinology
• Immunology

Background:

• Oceans harbor untapped potential for novel health solutions.
• Microalgae like Nannochloropsis spp. and Dunaliella salina are key resources for recombinant vaccine development.
• Marine organisms provide unique advantages for antigen expression and sustainable production.

Purpose of the Study:

• To explore the role of marine-derived substances in vaccine development.
• To highlight the potential of microalgae in producing recombinant antigens for human and animal health.
• To review the use of marine bioactive compounds as therapeutics, adjuvants, and delivery systems.

Main Methods:

• Genetic tools used to enhance recombinant antigen production in microalgae (Dunaliella salina, Nannochloropsis spp.).
• Development of microalgae-derived vaccine prototypes against various pathogens.
• Identification and application of marine bioactive compounds for immunological benefits.

Main Results:

• Microalgae-produced antigens show potential against human diseases (HPV, HIV, HBV, influenza, Zika, Ebola, malaria, Staphylococcus aureus).
• Microalgae-derived vaccine prototypes are effective against animal diseases (foot-and-mouth disease, swine fever, vibriosis, white spot syndrome, Histophilus somni).
• Marine bioactive compounds enhance vaccine efficacy and contribute to general health.

Conclusions:

• Marine microalgae are a sustainable and effective platform for developing vaccines against a wide range of infectious diseases.
• Marine-derived bioactive compounds offer multifaceted benefits, including therapeutic, adjuvant, and immunomodulatory properties.
• The ocean represents a vital resource for advancing modern medicine and combating infectious diseases.